ARTÍCULO
Uso de albúmina a largo plazo en el paciente cirrótico. Revisión sistemática
Fecha
2023Registro en:
2711-2330, e 2711-2322
10.52784/27112330.164
Autor
Gonzalez Dominguez, Esteban Horacio
Marin Tirado, Henry Ariel
Torres Cueva, Gabriela De los angeles
Institución
Resumen
Cirrhosis is the final stage of chronic liver disease, has a high mortality and can be due to different etiologies. Albumin has three well-established indications: prevention of circulatory ysfunction induced by paracentesis, spontaneous bacterial peritonitis, and hepatorenal syndro-me, however, its long-term use is controversial. The objective of this review was to identify if the prolonged use of albumin has beneficial effects in the treatment of cirrhotic patients. Methodology. PubMed database was searched using the following terms: ("Liver Cirrhosis"[Mesh]) AND ("Serum Albumin"[Mesh] OR "Serum Albumin, Human"[Mesh]). Articles that did not meet the topic and those that were more than 5 years old were excluded, except for those relevant to the review. Results.It has been shown in several studies within the previous 4 years, that prolonged administration of albumin reduces mortality in cirrhotic patients. In addition, it results in a decrease in hospital ad-missions due to complications of cirrhosis, a decrease in the need for paracentesis and less use of albumin for other established indications, which offsets the costs derived from therapy. Conclusion. It is concluded based on the evidence presented, that the long-term use of albumin could be beneficial in patients with decompensated liver cirrhosis. However, other aspects of the therapy need to be addressed in further studies.